JP2005501012A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005501012A5 JP2005501012A5 JP2003503168A JP2003503168A JP2005501012A5 JP 2005501012 A5 JP2005501012 A5 JP 2005501012A5 JP 2003503168 A JP2003503168 A JP 2003503168A JP 2003503168 A JP2003503168 A JP 2003503168A JP 2005501012 A5 JP2005501012 A5 JP 2005501012A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- ring
- carbon atoms
- phenyl
- cycloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 224
- 125000004432 carbon atom Chemical group C* 0.000 claims 206
- 125000000753 cycloalkyl group Chemical group 0.000 claims 116
- 125000000217 alkyl group Chemical group 0.000 claims 107
- 239000003795 chemical substances by application Substances 0.000 claims 91
- 125000001072 heteroaryl group Chemical group 0.000 claims 89
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 67
- 125000005843 halogen group Chemical group 0.000 claims 62
- 125000003545 alkoxy group Chemical group 0.000 claims 58
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 58
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 57
- 229910052799 carbon Inorganic materials 0.000 claims 56
- 229910052739 hydrogen Inorganic materials 0.000 claims 54
- 239000001257 hydrogen Substances 0.000 claims 54
- -1 perfluoromethoxy Chemical group 0.000 claims 53
- 125000005842 heteroatom Chemical group 0.000 claims 51
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 50
- 229910052717 sulfur Inorganic materials 0.000 claims 50
- 238000000034 method Methods 0.000 claims 49
- 229910052757 nitrogen Inorganic materials 0.000 claims 49
- 229910052760 oxygen Inorganic materials 0.000 claims 49
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 48
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 34
- 239000003814 drug Substances 0.000 claims 29
- 229940079593 drug Drugs 0.000 claims 22
- 239000013543 active substance Substances 0.000 claims 19
- 125000003118 aryl group Chemical group 0.000 claims 19
- 150000002431 hydrogen Chemical class 0.000 claims 18
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 15
- 239000000203 mixture Substances 0.000 claims 15
- 150000003839 salts Chemical class 0.000 claims 15
- 125000002373 5 membered heterocyclic group Chemical group 0.000 claims 13
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims 13
- 125000005062 perfluorophenyl group Chemical group FC1=C(C(=C(C(=C1F)F)F)F)* 0.000 claims 13
- 125000001309 chloro group Chemical group Cl* 0.000 claims 9
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 7
- 206010012601 diabetes mellitus Diseases 0.000 claims 7
- 125000001153 fluoro group Chemical group F* 0.000 claims 7
- 239000002253 acid Substances 0.000 claims 6
- 150000001721 carbon Chemical group 0.000 claims 6
- 125000004122 cyclic group Chemical group 0.000 claims 6
- 150000003254 radicals Chemical class 0.000 claims 6
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 claims 6
- 208000031226 Hyperlipidaemia Diseases 0.000 claims 5
- 208000008589 Obesity Diseases 0.000 claims 5
- 235000020824 obesity Nutrition 0.000 claims 5
- 206010003210 Arteriosclerosis Diseases 0.000 claims 4
- 201000001320 Atherosclerosis Diseases 0.000 claims 4
- 208000031773 Insulin resistance syndrome Diseases 0.000 claims 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 claims 4
- 159000000000 sodium salts Chemical class 0.000 claims 4
- IDBQCNOWFLIFPM-UHFFFAOYSA-N 4-[3-[(2,6-difluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC(OCC=2C(=CC=CC=2F)F)=C1 IDBQCNOWFLIFPM-UHFFFAOYSA-N 0.000 claims 3
- HFVDIZNJYLODRP-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCC(O)=O)=C1 HFVDIZNJYLODRP-UHFFFAOYSA-N 0.000 claims 3
- RKNUZODTBHBVDS-UHFFFAOYSA-N 4-[4-[(2,6-difluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=C(F)C=CC=C1F RKNUZODTBHBVDS-UHFFFAOYSA-N 0.000 claims 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims 3
- 125000000738 acetamido group Chemical group [H]C([H])([H])C(=O)N([H])[*] 0.000 claims 3
- 208000011775 arteriosclerosis disease Diseases 0.000 claims 3
- ISOLMABRZPQKOV-UHFFFAOYSA-N diethyl 2-acetamidopropanedioate Chemical compound CCOC(=O)C(NC(C)=O)C(=O)OCC ISOLMABRZPQKOV-UHFFFAOYSA-N 0.000 claims 3
- 208000010706 fatty liver disease Diseases 0.000 claims 3
- 230000007062 hydrolysis Effects 0.000 claims 3
- 238000006460 hydrolysis reaction Methods 0.000 claims 3
- 125000004356 hydroxy functional group Chemical group O* 0.000 claims 3
- ZRLYRWYSWSKQAT-UHFFFAOYSA-N 1-[4-[(2,6-difluorophenyl)methoxy]phenyl]-2-(1h-1,2,4-triazol-5-ylsulfanyl)ethanone Chemical compound FC1=CC=CC(F)=C1COC1=CC=C(C(=O)CSC2=NNC=N2)C=C1 ZRLYRWYSWSKQAT-UHFFFAOYSA-N 0.000 claims 2
- WTGWNWGXYQQSBM-UHFFFAOYSA-N 3-[[4-[(2,6-difluorophenyl)methoxy]phenyl]methylsulfanyl]propanoic acid Chemical compound C1=CC(CSCCC(=O)O)=CC=C1OCC1=C(F)C=CC=C1F WTGWNWGXYQQSBM-UHFFFAOYSA-N 0.000 claims 2
- MTYCLIQVKSXZNI-UHFFFAOYSA-N 3-[[4-[(2-fluorophenyl)methoxy]phenyl]methylsulfanyl]propanoic acid Chemical compound C1=CC(CSCCC(=O)O)=CC=C1OCC1=CC=CC=C1F MTYCLIQVKSXZNI-UHFFFAOYSA-N 0.000 claims 2
- ZZKJZIUCLOKLOT-UHFFFAOYSA-N 4-(2,6-difluorophenyl)-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=C(F)C=CC=C1F ZZKJZIUCLOKLOT-UHFFFAOYSA-N 0.000 claims 2
- PYEMFJAZILFLEZ-UHFFFAOYSA-N 4-[2-[(2,6-difluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC=C1OCC1=C(F)C=CC=C1F PYEMFJAZILFLEZ-UHFFFAOYSA-N 0.000 claims 2
- SXKZIRGKCPDSJS-UHFFFAOYSA-N 4-[3-(cyclobutylmethoxy)phenyl]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC(OCC2CCC2)=C1 SXKZIRGKCPDSJS-UHFFFAOYSA-N 0.000 claims 2
- WTEYVRDKSWAGRY-UHFFFAOYSA-N 4-[3-(cyclopropylmethoxy)phenyl]-4-oxobutanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC(OCC2CC2)=C1 WTEYVRDKSWAGRY-UHFFFAOYSA-N 0.000 claims 2
- RXZRQBLNAOLBLK-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-2,2-dimethyl-4-oxobutanoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CC(C)(C)C(O)=O)=C1 RXZRQBLNAOLBLK-UHFFFAOYSA-N 0.000 claims 2
- WBVJSANXEOFELZ-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobut-2-enoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)C=CC(O)=O)=C1 WBVJSANXEOFELZ-UHFFFAOYSA-N 0.000 claims 2
- HCMDUZDOYGHGHA-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]but-3-enoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C=CCC(O)=O)=C1 HCMDUZDOYGHGHA-UHFFFAOYSA-N 0.000 claims 2
- FMWZELKYUWYZRY-UHFFFAOYSA-N 4-[3-[(2-fluoro-6-methylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC(F)=C1COC1=CC=CC(C(=O)CCC(O)=O)=C1 FMWZELKYUWYZRY-UHFFFAOYSA-N 0.000 claims 2
- BPNPEIBOTNDLQS-UHFFFAOYSA-N 4-[3-[(2-methylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC=C1COC1=CC=CC(C(=O)CCC(O)=O)=C1 BPNPEIBOTNDLQS-UHFFFAOYSA-N 0.000 claims 2
- UJDZBVRDKDTYOK-UHFFFAOYSA-N 4-[4-(cyclopropylmethoxy)phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1CC1 UJDZBVRDKDTYOK-UHFFFAOYSA-N 0.000 claims 2
- YWICWJIZWROWLT-UHFFFAOYSA-N 4-[4-[(2,4-difluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=C(F)C=C1F YWICWJIZWROWLT-UHFFFAOYSA-N 0.000 claims 2
- IIMUHSVNELGECO-UHFFFAOYSA-N 4-[4-[(2,5-difluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC(F)=CC=C1F IIMUHSVNELGECO-UHFFFAOYSA-N 0.000 claims 2
- PHMAORJRWUGBPH-UHFFFAOYSA-N 4-[4-[(2,5-dimethylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=C(C)C(COC=2C=CC(=CC=2)C(=O)CCC(O)=O)=C1 PHMAORJRWUGBPH-UHFFFAOYSA-N 0.000 claims 2
- RUZNKCMDWMGNMH-UHFFFAOYSA-N 4-[4-[(2-fluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC=C1F RUZNKCMDWMGNMH-UHFFFAOYSA-N 0.000 claims 2
- TYMHUUBNSLQDHP-UHFFFAOYSA-N 4-[4-[(2-methoxyphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound COC1=CC=CC=C1COC1=CC=C(C(=O)CCC(O)=O)C=C1 TYMHUUBNSLQDHP-UHFFFAOYSA-N 0.000 claims 2
- YADLQEFRHHBMGQ-UHFFFAOYSA-N 4-[4-[(2-methylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC=C1COC1=CC=C(C(=O)CCC(O)=O)C=C1 YADLQEFRHHBMGQ-UHFFFAOYSA-N 0.000 claims 2
- ZCIVADXEDZSLOX-UHFFFAOYSA-N 4-[4-[(3-fluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC(F)=C1 ZCIVADXEDZSLOX-UHFFFAOYSA-N 0.000 claims 2
- MDLPYASYXFVKIX-UHFFFAOYSA-N 4-[4-[(4-fluorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=C(F)C=C1 MDLPYASYXFVKIX-UHFFFAOYSA-N 0.000 claims 2
- BASURFQVOZJAFE-UHFFFAOYSA-N 4-oxo-4-(4-phenylmethoxyphenyl)butanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC=C1 BASURFQVOZJAFE-UHFFFAOYSA-N 0.000 claims 2
- PQESJEIAPIVSIE-UHFFFAOYSA-N 4-oxo-4-[3-[[4-(trifluoromethyl)phenyl]methoxy]phenyl]butanoic acid Chemical compound OC(=O)CCC(=O)C1=CC=CC(OCC=2C=CC(=CC=2)C(F)(F)F)=C1 PQESJEIAPIVSIE-UHFFFAOYSA-N 0.000 claims 2
- PNDZWGOLDKGBQI-UHFFFAOYSA-N 4-oxo-4-[4-(2-thiophen-2-ylethoxy)phenyl]butanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCCC1=CC=CS1 PNDZWGOLDKGBQI-UHFFFAOYSA-N 0.000 claims 2
- VDHNOKVRILUICI-UHFFFAOYSA-N 4-oxo-4-[4-(pyridin-2-ylmethoxy)phenyl]butanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC=N1 VDHNOKVRILUICI-UHFFFAOYSA-N 0.000 claims 2
- ZGYBTRJTTITVRP-UHFFFAOYSA-N 4-oxo-4-[4-[[2-(trifluoromethyl)phenyl]methoxy]phenyl]butanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC=C1C(F)(F)F ZGYBTRJTTITVRP-UHFFFAOYSA-N 0.000 claims 2
- LBUKEYAVZKPGSA-UHFFFAOYSA-N 5-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-n-hydroxy-5-oxopentanamide Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCCC(=O)NO)=C1 LBUKEYAVZKPGSA-UHFFFAOYSA-N 0.000 claims 2
- YYRQECAOVDIPKD-UHFFFAOYSA-N 5-[[4-[(2,6-difluorophenyl)methoxy]phenyl]methyl]-2h-tetrazole Chemical compound FC1=CC=CC(F)=C1COC(C=C1)=CC=C1CC1=NN=NN1 YYRQECAOVDIPKD-UHFFFAOYSA-N 0.000 claims 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims 2
- 206010006895 Cachexia Diseases 0.000 claims 2
- 208000002177 Cataract Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 125000003047 N-acetyl group Chemical group 0.000 claims 2
- 208000017442 Retinal disease Diseases 0.000 claims 2
- 206010038923 Retinopathy Diseases 0.000 claims 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 claims 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- GKXFLBOJFVMQMC-UHFFFAOYSA-N ethyl 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound CCOC(=O)CCC(=O)C1=CC=CC(OCC=2C(=CC=CC=2C)C)=C1 GKXFLBOJFVMQMC-UHFFFAOYSA-N 0.000 claims 2
- QRWZIMJKESHEIK-UHFFFAOYSA-N ethyl 4-[3-[(2-fluorophenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound CCOC(=O)CCC(=O)C1=CC=CC(OCC=2C(=CC=CC=2)F)=C1 QRWZIMJKESHEIK-UHFFFAOYSA-N 0.000 claims 2
- RBQRGKLDPWTLBI-UHFFFAOYSA-N ethyl 4-[4-[(2,6-difluorophenyl)methoxy]phenyl]-3-oxobutanoate Chemical compound C1=CC(CC(=O)CC(=O)OCC)=CC=C1OCC1=C(F)C=CC=C1F RBQRGKLDPWTLBI-UHFFFAOYSA-N 0.000 claims 2
- LOFPPLZWUJAFSF-UHFFFAOYSA-N ethyl 4-[4-[(2,6-difluorophenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound C1=CC(C(=O)CCC(=O)OCC)=CC=C1OCC1=C(F)C=CC=C1F LOFPPLZWUJAFSF-UHFFFAOYSA-N 0.000 claims 2
- IHPRBYXMSSECDE-UHFFFAOYSA-N ethyl 4-[4-[(2-fluorophenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound C1=CC(C(=O)CCC(=O)OCC)=CC=C1OCC1=CC=CC=C1F IHPRBYXMSSECDE-UHFFFAOYSA-N 0.000 claims 2
- DDRNZSBOEUQHSX-UHFFFAOYSA-N ethyl 4-[4-[(2-methylphenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound C1=CC(C(=O)CCC(=O)OCC)=CC=C1OCC1=CC=CC=C1C DDRNZSBOEUQHSX-UHFFFAOYSA-N 0.000 claims 2
- 229960004580 glibenclamide Drugs 0.000 claims 2
- ZNNLBTZKUZBEKO-UHFFFAOYSA-N glyburide Chemical compound COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 ZNNLBTZKUZBEKO-UHFFFAOYSA-N 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 208000017169 kidney disease Diseases 0.000 claims 2
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims 2
- 229960003105 metformin Drugs 0.000 claims 2
- 125000000896 monocarboxylic acid group Chemical group 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 208000033808 peripheral neuropathy Diseases 0.000 claims 2
- HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 208000024891 symptom Diseases 0.000 claims 2
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 2
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 claims 1
- VGIIILXIQLXVLC-UHFFFAOYSA-N 1-(2,6-difluorophenyl)ethanone Chemical compound CC(=O)C1=C(F)C=CC=C1F VGIIILXIQLXVLC-UHFFFAOYSA-N 0.000 claims 1
- GMSFOWMGHGGASO-UHFFFAOYSA-N 4-[3-[(2,6-dimethoxyphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound COC1=CC=CC(OC)=C1COC1=CC=CC(C(=O)CCC(O)=O)=C1 GMSFOWMGHGGASO-UHFFFAOYSA-N 0.000 claims 1
- KXSGVMUZQVYWGQ-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanamide Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCC(N)=O)=C1 KXSGVMUZQVYWGQ-UHFFFAOYSA-N 0.000 claims 1
- UVELCWAZKCIXFE-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]but-2-enoic acid Chemical compound CC1=C(COC=2C=C(C=CC2)CC=CC(=O)O)C(=CC=C1)C UVELCWAZKCIXFE-UHFFFAOYSA-N 0.000 claims 1
- AGNWHTQVIMPQMA-UHFFFAOYSA-N 4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]butanoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=CC(CCCC(O)=O)=C1 AGNWHTQVIMPQMA-UHFFFAOYSA-N 0.000 claims 1
- ZUYMGXNRJNNFRU-UHFFFAOYSA-N 4-[4-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound CC1=CC=CC(C)=C1COC1=CC=C(C(=O)CCC(O)=O)C=C1 ZUYMGXNRJNNFRU-UHFFFAOYSA-N 0.000 claims 1
- OYDBQEXJQFGKRI-UHFFFAOYSA-N 4-[4-[(2-chlorophenyl)methoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCC1=CC=CC=C1Cl OYDBQEXJQFGKRI-UHFFFAOYSA-N 0.000 claims 1
- YAEMFPUTWSADIK-UHFFFAOYSA-N 4-[4-[2-(2-fluorophenyl)ethoxy]phenyl]-4-oxobutanoic acid Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1OCCC1=CC=CC=C1F YAEMFPUTWSADIK-UHFFFAOYSA-N 0.000 claims 1
- HCEQQASHRRPQFE-UHFFFAOYSA-N 5-chloro-n-[2-[4-(cyclohexylcarbamoylsulfamoyl)phenyl]ethyl]-2-methoxybenzamide;3-(diaminomethylidene)-1,1-dimethylguanidine;hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N.COC1=CC=C(Cl)C=C1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCCCC2)C=C1 HCEQQASHRRPQFE-UHFFFAOYSA-N 0.000 claims 1
- 208000037260 Atherosclerotic Plaque Diseases 0.000 claims 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 claims 1
- XUKUURHRXDUEBC-UHFFFAOYSA-N Atorvastatin Natural products C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CCC(O)CC(O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-UHFFFAOYSA-N 0.000 claims 1
- VXBMOSYMNUYPJW-UHFFFAOYSA-N CCC(CC)C(=O)NC(CC(=O)O)(C(=O)O)O Chemical compound CCC(CC)C(=O)NC(CC(=O)O)(C(=O)O)O VXBMOSYMNUYPJW-UHFFFAOYSA-N 0.000 claims 1
- 229910021589 Copper(I) bromide Inorganic materials 0.000 claims 1
- HLMXBKPSIINQMN-UHFFFAOYSA-N FC1=C(C=CC=C1)CCOC1=CC=C(C=C1)C(CCC(=O)O)=O.ClC1=C(COC2=CC=C(C=C2)C(CCC(=O)O)=O)C=CC=C1 Chemical compound FC1=C(C=CC=C1)CCOC1=CC=C(C=C1)C(CCC(=O)O)=O.ClC1=C(COC2=CC=C(C=C2)C(CCC(=O)O)=O)C=CC=C1 HLMXBKPSIINQMN-UHFFFAOYSA-N 0.000 claims 1
- HEMJJKBWTPKOJG-UHFFFAOYSA-N Gemfibrozil Chemical compound CC1=CC=C(C)C(OCCCC(C)(C)C(O)=O)=C1 HEMJJKBWTPKOJG-UHFFFAOYSA-N 0.000 claims 1
- FAEKWTJYAYMJKF-QHCPKHFHSA-N GlucoNorm Chemical compound C1=C(C(O)=O)C(OCC)=CC(CC(=O)N[C@@H](CC(C)C)C=2C(=CC=CC=2)N2CCCCC2)=C1 FAEKWTJYAYMJKF-QHCPKHFHSA-N 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- TUZYXOIXSAXUGO-UHFFFAOYSA-N Pravastatin Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(O)C=C21 TUZYXOIXSAXUGO-UHFFFAOYSA-N 0.000 claims 1
- RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 229960002632 acarbose Drugs 0.000 claims 1
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 claims 1
- 229910052783 alkali metal Inorganic materials 0.000 claims 1
- 150000001340 alkali metals Chemical class 0.000 claims 1
- 235000019270 ammonium chloride Nutrition 0.000 claims 1
- 229960005370 atorvastatin Drugs 0.000 claims 1
- 239000002585 base Substances 0.000 claims 1
- 230000031709 bromination Effects 0.000 claims 1
- 238000005893 bromination reaction Methods 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 claims 1
- 229960001214 clofibrate Drugs 0.000 claims 1
- KNHUKKLJHYUCFP-UHFFFAOYSA-N clofibrate Chemical compound CCOC(=O)C(C)(C)OC1=CC=C(Cl)C=C1 KNHUKKLJHYUCFP-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 229960003627 gemfibrozil Drugs 0.000 claims 1
- 229940112611 glucovance Drugs 0.000 claims 1
- 150000004820 halides Chemical class 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 208000019423 liver disease Diseases 0.000 claims 1
- 229960004844 lovastatin Drugs 0.000 claims 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims 1
- QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical compound CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 229960005095 pioglitazone Drugs 0.000 claims 1
- XZNXDIVSXSZJCF-UHFFFAOYSA-M potassium;4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound [K+].CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCC([O-])=O)=C1 XZNXDIVSXSZJCF-UHFFFAOYSA-M 0.000 claims 1
- 229960002965 pravastatin Drugs 0.000 claims 1
- TUZYXOIXSAXUGO-PZAWKZKUSA-N pravastatin Chemical compound C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC(O)=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 TUZYXOIXSAXUGO-PZAWKZKUSA-N 0.000 claims 1
- KOODSCBKXPPKHE-UHFFFAOYSA-N propanethioic s-acid Chemical compound CCC(S)=O KOODSCBKXPPKHE-UHFFFAOYSA-N 0.000 claims 1
- 229960002354 repaglinide Drugs 0.000 claims 1
- 229960004586 rosiglitazone Drugs 0.000 claims 1
- FZHAPNGMFPVSLP-UHFFFAOYSA-N silanamine Chemical compound [SiH3]N FZHAPNGMFPVSLP-UHFFFAOYSA-N 0.000 claims 1
- 229960002855 simvastatin Drugs 0.000 claims 1
- RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims 1
- VNHHVCKIXSNTHE-UHFFFAOYSA-M sodium;4-[3-[(2,6-dimethylphenyl)methoxy]phenyl]-4-oxobutanoate Chemical compound [Na+].CC1=CC=CC(C)=C1COC1=CC=CC(C(=O)CCC([O-])=O)=C1 VNHHVCKIXSNTHE-UHFFFAOYSA-M 0.000 claims 1
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000036269 ulceration Effects 0.000 claims 1
- 0 C*(c(c(F)ccc1)c1F)=C Chemical compound C*(c(c(F)ccc1)c1F)=C 0.000 description 10
- RDOXTESZEPMUJZ-UHFFFAOYSA-N COc1ccccc1 Chemical compound COc1ccccc1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- YXFVVABEGXRONW-UHFFFAOYSA-N Cc1ccccc1 Chemical compound Cc1ccccc1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Oc1ccccc1 Chemical compound Oc1ccccc1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US29728201P | 2001-06-12 | 2001-06-12 | |
| US60/297,282 | 2001-06-12 | ||
| PCT/US2002/018388 WO2002100341A2 (en) | 2001-06-12 | 2002-06-12 | Compounds for the treatment of metabolic disorders |
Related Child Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009161269A Division JP5477893B2 (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
| JP2009161270A Division JP2009221232A (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2005501012A JP2005501012A (ja) | 2005-01-13 |
| JP2005501012A5 true JP2005501012A5 (enExample) | 2006-01-05 |
| JP4711621B2 JP4711621B2 (ja) | 2011-06-29 |
Family
ID=23145636
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003503168A Expired - Lifetime JP4711621B2 (ja) | 2001-06-12 | 2002-06-12 | 代謝障害治療用化合物 |
| JP2009161269A Expired - Fee Related JP5477893B2 (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
| JP2009161270A Pending JP2009221232A (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
| JP2013043951A Withdrawn JP2013129665A (ja) | 2001-06-12 | 2013-03-06 | 代謝障害治療用化合物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009161269A Expired - Fee Related JP5477893B2 (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
| JP2009161270A Pending JP2009221232A (ja) | 2001-06-12 | 2009-07-07 | 代謝障害治療用化合物 |
| JP2013043951A Withdrawn JP2013129665A (ja) | 2001-06-12 | 2013-03-06 | 代謝障害治療用化合物 |
Country Status (19)
| Country | Link |
|---|---|
| US (23) | US7101910B2 (enExample) |
| EP (1) | EP1461323B1 (enExample) |
| JP (4) | JP4711621B2 (enExample) |
| KR (4) | KR101059776B1 (enExample) |
| CN (4) | CN100344616C (enExample) |
| AU (3) | AU2002345625B2 (enExample) |
| BR (1) | BRPI0210383B1 (enExample) |
| CA (1) | CA2450221C (enExample) |
| CZ (1) | CZ20033394A3 (enExample) |
| ES (1) | ES2441874T3 (enExample) |
| HU (1) | HU230352B1 (enExample) |
| IL (5) | IL159320A0 (enExample) |
| MX (1) | MXPA03011558A (enExample) |
| NO (2) | NO333355B1 (enExample) |
| NZ (1) | NZ530051A (enExample) |
| RU (2) | RU2341513C2 (enExample) |
| UA (2) | UA104987C2 (enExample) |
| WO (1) | WO2002100341A2 (enExample) |
| ZA (1) | ZA200309627B (enExample) |
Families Citing this family (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6670358B2 (en) | 2000-05-16 | 2003-12-30 | Cephalon, Inc. | Substituted thioacetamides |
| RU2341513C2 (ru) * | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| PL373586A1 (en) * | 2002-01-11 | 2005-09-05 | Abbott Laboratories | Histamine-3 receptor ligands for diabetic conditions |
| CA2502297C (en) * | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2530235T3 (es) * | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| ES2353601T3 (es) | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| CN1777576A (zh) * | 2003-04-22 | 2006-05-24 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| EA200501710A1 (ru) | 2003-04-30 | 2006-06-30 | ДЗЕ ИНСТИТЬЮТС ФОР ФАРМАСЬЮТИКАЛ ДИСКАВЕРИ, ЭлЭлСи | Замещённые карбоновые кислоты |
| CA2522738C (en) * | 2003-04-30 | 2011-11-08 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| BRPI0412684A (pt) * | 2003-07-17 | 2006-10-03 | Plexxinko Inc | compostos ppar-ativos |
| US7348338B2 (en) * | 2003-07-17 | 2008-03-25 | Plexxikon, Inc. | PPAR active compounds |
| MXPA06001963A (es) * | 2003-08-20 | 2006-05-31 | Wellstat Therapeutics Corp | Compuestos para el tratamiento de trastornos metabolicos. |
| CA2560928A1 (en) * | 2004-03-29 | 2005-10-06 | Sankyo Company Limited | Therapeutic agent for diabetes containing insulin resistance improving agent |
| US7297817B2 (en) * | 2004-04-13 | 2007-11-20 | Cephalon France | Thio-substituted arylmethanesulfinyl derivatives |
| US7119214B2 (en) * | 2004-04-13 | 2006-10-10 | Cephalon France | Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives |
| US7314875B2 (en) * | 2004-04-13 | 2008-01-01 | Cephalon, Inc. | Tricyclic aromatic and bis-phenyl sulfinyl derivatives |
| EP1586560A1 (en) * | 2004-04-13 | 2005-10-19 | Cephalon, Inc. | Thio-substituted arylmethanesulfinyl derivatives |
| US7449481B2 (en) * | 2004-04-13 | 2008-11-11 | Cephalon, Inc. | Thio-substituted biaryl-methanesulfinyl derivatives |
| US7423176B2 (en) * | 2004-04-13 | 2008-09-09 | Cephalon, Inc. | Bicyclic aromatic sulfinyl derivatives |
| JP2008518926A (ja) * | 2004-10-28 | 2008-06-05 | ジ インスティチューツ フォー ファーマシューティカル ディスカバリー、エルエルシー | 置換フェニルアルカン酸 |
| US8394765B2 (en) * | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| EP1819673A2 (en) * | 2004-11-30 | 2007-08-22 | Plexxikon, Inc. | Indole derivatives for use as ppar active compounds |
| WO2006063294A2 (en) * | 2004-12-09 | 2006-06-15 | Kalypsys, Inc. | Novel inhibitors of histone deacetylase for the treatment of disease |
| WO2006127133A2 (en) | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US9370539B2 (en) | 2005-06-10 | 2016-06-21 | Donald E. Scott | Topical compositions and methods for alleviating or inhibiting symptoms associated with carpal tunnel syndrome, acid reflux, psoriasis, cartilage nodules, fibromyalgia, and diabetes |
| KR101363278B1 (ko) * | 2005-06-27 | 2014-02-21 | 엑셀리시스 페이턴트 컴퍼니 엘엘씨 | 이미다졸계 ｌｘｒ 변조제 |
| CA2621474A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1,3-disubstituted indole derivatives for use as ppar modulators |
| CA2621275A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | 1 , 4 and 1 , 5-disubstituted indole derivatives for use as ppar active compounds |
| CA2621406A1 (en) * | 2005-09-07 | 2007-03-15 | Plexxikon, Inc. | Pparactive compounds |
| WO2007036041A1 (en) * | 2005-09-28 | 2007-04-05 | Suleiman Igdoura | Sialidase inhibitors for the treatment of cardiovascular disease |
| UA95613C2 (ru) * | 2005-11-09 | 2011-08-25 | Уеллстат Терепьютикс Корпорейшн | Соединения для лечения расстройсв метаболизма |
| CA2634940A1 (en) * | 2005-12-21 | 2007-07-05 | Schering Corporation | Treatment of nonalcoholic fatty liver disease using cholesterol lowering agents and h3 receptor antagonist/inverse agonist |
| US20070155707A1 (en) * | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
| AU2007208127A1 (en) * | 2006-01-25 | 2007-08-02 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| EP1976510A4 (en) * | 2006-01-25 | 2010-06-09 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLISM DISORDER |
| US7820721B2 (en) * | 2006-01-25 | 2010-10-26 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| JP2009525982A (ja) | 2006-02-02 | 2009-07-16 | ウェルスタット セラピューティクス コーポレイション | 代謝障害の治療のための化合物 |
| EP1983972A4 (en) * | 2006-02-13 | 2012-01-25 | Wellstat Therapeutics Corp | COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS |
| KR20080098615A (ko) * | 2006-02-28 | 2008-11-11 | 웰스태트 테러퓨틱스 코포레이션 | 물질대사 장애의 치료용 화합물 |
| WO2007117791A2 (en) | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
| US20070238183A1 (en) * | 2006-04-04 | 2007-10-11 | Stout Robert L | Methods for assessment of cardiovascular disease risk |
| CA2651598A1 (en) * | 2006-05-18 | 2007-11-29 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US20100234464A1 (en) * | 2006-06-09 | 2010-09-16 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| CA2661293A1 (en) | 2006-08-17 | 2008-02-21 | Wellstat Therapeutics Corporation | Combination treatment for metabolic disorders |
| US20080089845A1 (en) * | 2006-09-07 | 2008-04-17 | N.V. Organon | Methods for determining effective doses of fatty acid amide hydrolase inhibitors in vivo |
| US20090099240A1 (en) * | 2006-10-02 | 2009-04-16 | N.V. Organon | Methods for treating energy metabolism disorders by inhibiting fatty acid amide hydrolase activity |
| EP2096915A1 (en) * | 2006-11-20 | 2009-09-09 | N.V. Organon | Metabolically-stabilized inhibitors of fatty acid amide hydrolase |
| EP2121621B1 (en) | 2006-12-08 | 2014-05-07 | Exelixis Patent Company LLC | Lxr and fxr modulators |
| PE20090159A1 (es) * | 2007-03-08 | 2009-02-21 | Plexxikon Inc | COMPUESTOS DERIVADOS DE ACIDO INDOL-PROPIONICO COMO MODULADORES PPARs |
| US11241420B2 (en) | 2007-04-11 | 2022-02-08 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2008128126A1 (en) * | 2007-04-11 | 2008-10-23 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| US20160331729A9 (en) | 2007-04-11 | 2016-11-17 | Omeros Corporation | Compositions and methods for prophylaxis and treatment of addictions |
| WO2009091732A1 (en) * | 2008-01-15 | 2009-07-23 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| US8829058B2 (en) * | 2008-03-13 | 2014-09-09 | Wellstat Therapeutics Corporation | Compounds and method for reducing uric acid |
| US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
| KR101037178B1 (ko) * | 2008-04-10 | 2011-05-26 | 건국대학교 산학협력단 | 비뉴클레오시드 계열의 ｃ형 간염 치료 또는 예방제 |
| MX2010011603A (es) * | 2008-04-30 | 2011-01-25 | Wellstat Therapeutics Corp | Compuestos de tetrazol para reducir el acido urico. |
| WO2009137381A1 (en) * | 2008-05-05 | 2009-11-12 | Wellstat Therapeutics Corporation | Synthesis of 4-[3-(2,6-dimethylbenzyloxy)phenyl]-4-oxobutanoic acid |
| EP2365746B1 (en) | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthesis of (phenylalkyloxy)phenyl-oxobutanoic acids |
| CN102548393B (zh) * | 2009-07-31 | 2015-06-03 | 斯特里克再生医学学院,斯特里克学院事务所 | 脂肪性肝炎-肝癌模型动物 |
| WO2011046800A1 (en) | 2009-10-13 | 2011-04-21 | Wellstat Therapeutics Corporation | 3-substituted compounds for reducing uric acid |
| US20130331452A1 (en) | 2010-09-08 | 2013-12-12 | Wellstat Therapeutics Corporation | Benzoic acid compounds for reducing uric acid |
| WO2012112447A2 (en) * | 2011-02-14 | 2012-08-23 | Dana-Farber Cancer Institute, Inc. | Histone deacetylase inhibitors and methods of use thereof |
| FR2974065B1 (fr) * | 2011-04-14 | 2013-05-10 | Snecma | Procede de montage d'un moteur d'aeronef sur un pylone et attache moteur pour la mise en oeuvre d'un tel procede. |
| FR2976942B1 (fr) | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| FR2976943B1 (fr) * | 2011-06-23 | 2013-07-12 | Metabolys | Derives de piperazine, leurs procedes de preparation et leurs utilisations dans le traitement de l'insulinoresistance |
| FR2999427B1 (fr) | 2012-12-17 | 2015-01-30 | Metabolys | Composition et kit comprenant des derives de piperazine et de la metformine, leur utilisation dans le traitement du diabete |
| JP6457527B2 (ja) * | 2013-12-11 | 2019-01-23 | バイエル・クロップサイエンス・アクチェンゲゼルシャフト | ハロゲン化ジ置換ベンジルアミン類、特にハロゲン化ジアルキルベンジルアミン類の製造方法 |
| US20190038650A1 (en) * | 2016-02-01 | 2019-02-07 | Babak Razani | Compositions and methods for the treatment of atherosclerosis and hepatosteatosis and other diseases |
| EP3278802A1 (en) * | 2016-08-04 | 2018-02-07 | Metabolys | New treatment for the non alcoholic steatohepatitis and fibrosis |
| CN108610285B (zh) * | 2017-03-17 | 2020-04-28 | 上海柏翱纳吉医药科技有限公司 | 苯乙酮类化合物、其制备方法及其在防治脂肪肝方面的应用 |
| WO2019224393A1 (en) * | 2018-05-25 | 2019-11-28 | University Of Copenhagen | Fenofibrate for reducing hypoglycemia in type 1 diabetes/lada |
| MA53188A1 (fr) * | 2018-10-11 | 2021-12-31 | Basf As | Composés aromatiques et leurs utilisations pharmaceutiques |
| CN113134086B (zh) * | 2020-01-20 | 2024-05-24 | 深圳市长卿医学研究院 | 一种降血脂的药物组合物 |
Family Cites Families (141)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR5035E (fr) | 1902-08-29 | 1905-12-02 | Paul Wilhelm Sieurin | Engin à puiser à fond de cale des navires et à élever des matières |
| GB148830A (en) | 1918-12-04 | 1921-11-10 | Aegir Electrische Bordapp Und | Device for signalling liquid levels at a distance |
| BE667498A (enExample) * | 1964-07-28 | 1965-11-16 | ||
| CH560193A5 (enExample) | 1968-06-14 | 1975-03-27 | Ciba Geigy Ag | |
| JPS4725149U (enExample) | 1971-04-14 | 1972-11-21 | ||
| BE787782A (fr) * | 1971-08-20 | 1973-02-19 | Thomae Gmbh Dr K | Nouveaux 4-(4-biphenylyl)-butyramides |
| GB1437781A (en) * | 1972-04-04 | 1976-06-03 | Beecham Group Ltd | Pyridine derivatives having hypoglycaemic activity |
| FR2191887A1 (en) | 1972-07-07 | 1974-02-08 | Ugine Kuhlmann | 7-Substd 5-hydroxy-imidazo pyrimidines - antiinflammatories, and immuno-suppressives, from 2-aminoimidazoline and substd ethyl acetates |
| DE2252818A1 (de) * | 1972-10-27 | 1974-05-09 | Nippon Soda Co | Aralkylarylaether oder -thioaether und ihre verwendung als regulatoren fuer das pflanzenwachstum |
| DE2309986A1 (de) * | 1973-02-28 | 1974-08-29 | Menarini Sas | N-(o-hydroxybenzoyl)-p-(2-dialkylaminoaethoxy)-phenylamine sowie osubstituierte derivate und quartaere salze derselben |
| NL7307100A (en) | 1973-05-22 | 1974-11-26 | 1,3-dimethylpyrogallol derivs pharmaceutical inters - prepd. from (3,5-dimethoxy-benzyloxybenzoyl)acetic acid methyl ester and sulphurylchloride | |
| GB1482195A (en) * | 1973-08-23 | 1977-08-10 | Beecham Group Ltd | Biologically active phenyl(thio)ether derivatives |
| IL45396A0 (en) * | 1973-08-23 | 1974-11-29 | Beecham Group Ltd | Pharmaceutical compositions containing aryl aralkyl ether and thioether derivatives,certain such novel compounds and their preparation |
| US4098816A (en) * | 1973-08-23 | 1978-07-04 | Beecham Group Limited | Polycyclic oxy-aromatic acid |
| US4011321A (en) | 1973-12-19 | 1977-03-08 | Smith Kline & French Laboratories Limited | Pharmaceutical compositions and methods of inhibiting β-adrenergic receptors |
| GB1488330A (en) | 1973-12-19 | 1977-10-12 | Smith Kline French Lab | Dihydropyridazinones |
| JPS5811874B2 (ja) | 1974-03-25 | 1983-03-04 | 武田薬品工業株式会社 | ピリド （３，４−ｄ） ピリダジンルイノ セイゾウホウ |
| IE42214B1 (en) | 1974-06-18 | 1980-07-02 | Smith Kline French Lab | Hydrazinopyredazines |
| GB1479759A (en) * | 1974-11-23 | 1977-07-13 | Lepetit Spa | Heterocyclic fused derivatives of indole and quinoline |
| JPS5225734A (en) * | 1975-08-23 | 1977-02-25 | Kyorin Pharmaceut Co Ltd | Process for preparation of 4-(4'-halogenobenzyloxy)-bonzoyl acetate |
| JPS5515460A (en) * | 1978-07-20 | 1980-02-02 | Hisamitsu Pharmaceut Co Inc | Novel 2-substituted-benzoylpropionic acid derivative |
| EP0011279B1 (en) * | 1978-11-14 | 1982-05-05 | Sagami Chemical Research Center | Process for the preparation of aromatically substituted acetic acids |
| JPS56115747A (en) | 1980-02-19 | 1981-09-11 | Nippon Synthetic Chem Ind Co Ltd:The | 2- 2-hydroxyethylamino -3-substituted benzoylpropionic acid, its preparation and germicide |
| DE3012012A1 (de) | 1980-03-28 | 1981-10-08 | Beiersdorf Ag, 2000 Hamburg | Substituierte 3-aryl-2-cycloalken-1-one und verfahren zu ihrer herstellung |
| ZA825227B (en) | 1981-07-22 | 1984-03-28 | Syntex Inc | Substituted pyrrolidine cardiovascular system regulators antihypertensives |
| IT1171604B (it) | 1981-10-22 | 1987-06-10 | Roussel Maestretti Spa | Derivati di acido 4-fenil-4-ossobuten-2-oico dotati di proprieta' farmacologiche e loro procedimento di preparazione |
| DE3370616D1 (en) * | 1982-08-06 | 1987-05-07 | Ube Industries | Process for producing phenylacetones |
| US4474809A (en) * | 1983-01-20 | 1984-10-02 | American Cyanamid Company | Arylglyoxals |
| JPS6140270A (ja) | 1984-08-01 | 1986-02-26 | Morishita Seiyaku Kk | ピリダジノン誘導体 |
| US4874777A (en) | 1987-04-10 | 1989-10-17 | Eli Lilly And Company | Leukotriene antagonists |
| JPS63270661A (ja) | 1987-04-28 | 1988-11-08 | Taki Chem Co Ltd | １−〔２−（４−ヒドロキシベンゾイル）エタノイル〕−２−ピペリドン及びその製造法並びにそれを有効成分とするアルコ−ル発酵促進剤 |
| DE3720317A1 (de) * | 1987-06-19 | 1988-12-29 | Sandoz Ag | Neue allylaminderivate |
| JPS6438636A (en) * | 1987-08-05 | 1989-02-08 | Ajinomoto Kk | Fluorescent analyzer |
| JPS6463570A (en) | 1987-09-03 | 1989-03-09 | Taki Chemical | 1-(3-(4-hydroxyphenyl)-3-hydroxypropanoyl)-2-piperidone, its production and plant growth regulator therefrom |
| JPH041023Y2 (enExample) | 1987-10-20 | 1992-01-14 | ||
| JP2534744B2 (ja) | 1988-01-13 | 1996-09-18 | 株式会社リコー | カラ―画像符号化方式 |
| US4845231A (en) | 1988-02-12 | 1989-07-04 | American Home Products Corporation | Tetrazoles and their use as hypoglycemic agents |
| GB8804457D0 (en) | 1988-02-25 | 1988-03-23 | Ciba Geigy Ag | Compositions |
| JPH01216961A (ja) * | 1988-02-25 | 1989-08-30 | Takeda Chem Ind Ltd | １２−リポキシゲネース阻害剤 |
| CA2012681A1 (en) | 1989-03-31 | 1990-09-30 | Masayasu Okuhira | Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same |
| US4895862A (en) * | 1989-04-21 | 1990-01-23 | American Home Products Corp. | Novel benzyl-3H-1,2,3,5-oxathiadiazole 2-oxides useful as antihyperglycemic agents |
| US4911555A (en) * | 1989-05-04 | 1990-03-27 | The Jackson Laboratory | Magnetic stirrer for multiple samples |
| DE3923093A1 (de) | 1989-07-13 | 1991-01-24 | Basf Ag | Neue 3-methoximinopropionsaeureester und diese enthaltende fungizide |
| JPH0348603A (ja) * | 1989-07-14 | 1991-03-01 | Wakayama Pref Gov | 抗菌防臭材料 |
| US6572862B1 (en) * | 1989-11-08 | 2003-06-03 | Baylor College Of Medicine | Methods and reagents to detect and characterize Norwalk and related viruses |
| AU6643290A (en) * | 1989-11-08 | 1991-06-13 | Baylor College Of Medicine | Methods and reagents to detect and characterize norwalk and related viruses |
| CA2029219A1 (en) * | 1989-11-08 | 1991-05-09 | Mary K. Estes | Methods and reagents to detect and characterize norwalk and related viruses |
| US5149737A (en) * | 1990-06-18 | 1992-09-22 | Eastman Kodak Company | Carboxy containing monomers and polymers and latices prepared from same |
| DE69113874T2 (de) * | 1990-06-21 | 1996-03-28 | Zeneca Ltd | Zyklische Ether-Derivate. |
| AU638840B2 (en) * | 1990-07-05 | 1993-07-08 | Sumitomo Chemical Company, Limited | Pyrimidine derivative |
| JPH0495049A (ja) * | 1990-08-08 | 1992-03-27 | Asahi Chem Ind Co Ltd | ビフェニル‐５，５’‐ビス‐アルカン酸誘導体、その製造法およびその用途 |
| JPH04159266A (ja) * | 1990-10-19 | 1992-06-02 | Fujisawa Pharmaceut Co Ltd | ピリミジノン誘導体 |
| CA2098020C (en) * | 1991-01-02 | 2003-10-21 | Daniel Schirlin | Anti-viral compounds |
| NL9100770A (nl) * | 1991-05-03 | 1992-12-01 | Hubertine Maria Emilie Aalders | Opslagdoos voor een bril en contactlenzen. |
| TW201311B (enExample) * | 1991-06-17 | 1993-03-01 | Hoffmann La Roche | |
| US5817693A (en) * | 1991-11-05 | 1998-10-06 | Cousins; Russell Donovan | Endothelin receptor antagonists |
| FI942059L (fi) | 1991-11-05 | 1994-07-04 | Smithkline Beecham Corp | Endoteliinireseptoreiden antagonisteja |
| JPH05230009A (ja) * | 1992-02-24 | 1993-09-07 | Taisho Pharmaceut Co Ltd | アミジン誘導体 |
| CA2150550A1 (en) * | 1992-12-01 | 1994-06-09 | Melissa S. Egbertson | Fibrinogen receptor antagonists |
| TW273551B (enExample) | 1993-05-24 | 1996-04-01 | Wakiei Seiyaku Kk | |
| US5591862A (en) * | 1993-06-11 | 1997-01-07 | Takeda Chemical Industries, Ltd. | Tetrazole derivatives, their production and use |
| IT1265101B1 (it) * | 1993-07-23 | 1996-10-30 | Erba Carlo Spa | Derivati dell'acido 2-ammino-4-fenil-4-osso butirrico |
| JPH09501920A (ja) * | 1993-08-19 | 1997-02-25 | ワーナー−ランバート・コンパニー | 非ペプチドエンドセリンアンタゴニスト▲ｉ▼ |
| IL111613A0 (en) | 1993-11-12 | 1995-01-24 | Rhone Poulenc Rorer Ltd | Substituted phenyl compounds, their preparation and pharmaceutical compositions containing them |
| US5665387A (en) | 1994-09-01 | 1997-09-09 | K.U. Leuven Research & Development | Methods and compositions for primary and secondary prevention of autoimmune diabetes |
| US5641796A (en) * | 1994-11-01 | 1997-06-24 | Eli Lilly And Company | Oral hypoglycemic agents |
| US20040135273A1 (en) * | 1995-06-27 | 2004-07-15 | Parker Jeffery R. | Methods of making a pattern of optical element shapes on a roll for use in making optical elements on or in substrates |
| US6712481B2 (en) * | 1995-06-27 | 2004-03-30 | Solid State Opto Limited | Light emitting panel assemblies |
| US5975711A (en) * | 1995-06-27 | 1999-11-02 | Lumitex, Inc. | Integrated display panel assemblies |
| US6185356B1 (en) * | 1995-06-27 | 2001-02-06 | Lumitex, Inc. | Protective cover for a lighting device |
| US5613751A (en) * | 1995-06-27 | 1997-03-25 | Lumitex, Inc. | Light emitting panel assemblies |
| US7108414B2 (en) * | 1995-06-27 | 2006-09-19 | Solid State Opto Limited | Light emitting panel assemblies |
| US20020058931A1 (en) * | 1995-06-27 | 2002-05-16 | Jeffrey R. Parker | Light delivery system and applications thereof |
| BR9611047A (pt) | 1995-10-17 | 2000-03-08 | Searle & Co | Processo de deteção de ciclo oxigenase-2 |
| GB9521486D0 (en) * | 1995-10-20 | 1995-12-20 | Pharmacia Spa | Fluoro-substituted benzoylpropionic acid derivatives |
| GB9522617D0 (en) * | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butenoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| GB9522615D0 (en) * | 1995-11-03 | 1996-01-03 | Pharmacia Spa | 4-Phenyl-4-oxo-butanoic acid derivatives with kynurenine-3-hydroxylase inhibiting activity |
| JP3906935B2 (ja) | 1995-12-18 | 2007-04-18 | 杏林製薬株式会社 | Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法 |
| IL125820A0 (en) | 1996-02-19 | 1999-04-11 | Japan Tobacco Inc | Therapeutic agent for diabetes and a pharmaceutical composition containing the same |
| AU3461697A (en) | 1996-07-19 | 1998-02-10 | Takeda Chemical Industries Ltd. | Heterocyclic compounds, their production and use |
| FR2752422B1 (fr) | 1996-08-16 | 1998-11-06 | Lipha | Composition pharmaceutique contenant des acides 4-oxo-butanoiques |
| KR100205768B1 (en) * | 1996-08-24 | 1999-07-01 | Choongwae Pharm Co | Stereo-selective composition of 4-acetoxyazetidinone |
| KR100343832B1 (ko) | 1996-08-27 | 2002-07-20 | 시오노기세이야쿠가부시키가이샤 | 크로멘-3-카르복실산 유도체 |
| AU725403B2 (en) * | 1996-09-13 | 2000-10-12 | Merck & Co., Inc. | Thrombin inhibitors |
| CA2216512A1 (en) * | 1996-10-11 | 1998-04-11 | Rohm And Haas Company | Dihydropyridazinones and pyridazinones their use as fungicides and insecticides |
| JPH10130241A (ja) | 1996-10-31 | 1998-05-19 | Wakunaga Pharmaceut Co Ltd | 新規ピリドンカルボン酸誘導体又はその塩及びこれを含有する医薬 |
| MXPA99001974A (es) | 1996-12-09 | 2002-03-27 | Warner Lambert Co | Metodo para tratar y prevenir fallas cardiacas y dilatacion ventricular. |
| IT1289238B1 (it) | 1996-12-10 | 1998-09-29 | Bio S S P A Ora Bio S S R L | Composizioni farmaceutiche per il trattamento di infezioni virali comprendenti una 4 arilcumarina |
| AU8750298A (en) * | 1997-08-28 | 1999-03-22 | Ono Pharmaceutical Co. Ltd. | Peroxisome proliferator-activated receptor controllers |
| US6038332A (en) | 1997-09-05 | 2000-03-14 | Digital Biometrics, Inc. | Method and apparatus for capturing the image of a palm |
| CA2304713C (en) | 1997-10-14 | 2003-06-10 | Asahi Kasei Kogyo Kabushiki Kaisha | Biphenyl-5-alkanoic acid derivatives and use thereof |
| AU9696198A (en) | 1997-10-17 | 1999-05-10 | Aventis Pharmaceuticals Products Inc. | Therapeutic uses of quinoline derivatives |
| JP3608929B2 (ja) | 1997-12-19 | 2005-01-12 | セントラル硝子株式会社 | ポリイミド組成物 |
| DE69941777D1 (de) * | 1998-03-10 | 2010-01-21 | Ono Pharmaceutical Co | Carbonsäurederivate und medikamente die diese als aktiven wirkstoff enthalten |
| BR9802163A (pt) | 1998-05-29 | 2000-11-28 | Ind E Com De Prod Farmaceutico | Composiçoes farmacêuticas para o tratamento de infecções virais compreendendo substâncias neoflavonoides (4-arilcumarinas) |
| AU4225499A (en) | 1998-06-03 | 1999-12-20 | Merck & Co., Inc. | Hiv integrase inhibitors |
| SE9801992D0 (sv) | 1998-06-04 | 1998-06-04 | Astra Ab | New 3-aryl-2-hydroxypropionic acid derivative I |
| WO1999063929A2 (en) | 1998-06-08 | 1999-12-16 | Advanced Medicine, Inc. | Multibinding inhibitors of microsomal triglyceride transferase protein |
| WO2000006996A1 (en) * | 1998-07-28 | 2000-02-10 | Ce Resources Pte Ltd. | Optical detection system |
| DE69912379T2 (de) * | 1998-08-14 | 2004-05-06 | Pfizer Inc. | Antithrombosemittel |
| US6255498B1 (en) | 1998-10-16 | 2001-07-03 | Millennium Pharmaceuticals, Inc. | Method for synthesizing diaryl-substituted heterocyclic compounds, including tetrahydrofurans |
| US6291503B1 (en) * | 1999-01-15 | 2001-09-18 | Bayer Aktiengesellschaft | β-phenylalanine derivatives as integrin antagonists |
| US6827456B2 (en) * | 1999-02-23 | 2004-12-07 | Solid State Opto Limited | Transreflectors, transreflector systems and displays and methods of making transreflectors |
| US7364341B2 (en) * | 1999-02-23 | 2008-04-29 | Solid State Opto Limited | Light redirecting films including non-interlockable optical elements |
| ATE508200T1 (de) * | 1999-02-23 | 2011-05-15 | Caliper Life Sciences Inc | Sequenzierung durch inkorporation |
| US6752505B2 (en) * | 1999-02-23 | 2004-06-22 | Solid State Opto Limited | Light redirecting films and film systems |
| US20050024849A1 (en) * | 1999-02-23 | 2005-02-03 | Parker Jeffery R. | Methods of cutting or forming cavities in a substrate for use in making optical films, components or wave guides |
| AU4250200A (en) | 1999-04-19 | 2000-11-02 | Coelacanth Corporation | Ppar-(gamma) agonists as agents for the treatment of type ii diabetes |
| WO2000068692A1 (en) * | 1999-05-07 | 2000-11-16 | Quantum Dot Corporation | A method of detecting an analyte using semiconductor nanocrystals |
| EP1065210A1 (en) | 1999-07-01 | 2001-01-03 | ASTA Medica Aktiengesellschaft | Novel xanthone compounds, their preparation and use as medicament |
| US6541521B1 (en) | 1999-07-12 | 2003-04-01 | Warner-Lambert Company | Benzene butyric acids and their derivatives as inhibitors of matrix metalloproteinases |
| US20030092058A1 (en) * | 1999-08-10 | 2003-05-15 | Spaulding Glenn F. | Novel flow cytometer |
| AU778282B2 (en) * | 1999-09-17 | 2004-11-25 | Kyorin Pharmaceutical Co. Ltd. | O-anisamide derivatives |
| JP2001181281A (ja) | 1999-10-12 | 2001-07-03 | Sato Pharmaceutical Co Ltd | 抗菌剤として有用なキノロン誘導体 |
| WO2001036351A2 (en) | 1999-11-19 | 2001-05-25 | Corvas International, Inc. | Plasminogen activator inhibitor antagonists related applications |
| TW574193B (en) | 1999-12-03 | 2004-02-01 | Astrazeneca Ab | Novel phenalkyloxy-phenyl derivatives, pharmaceutical composition containing the same and their uses |
| US6610351B2 (en) * | 2000-04-12 | 2003-08-26 | Quantag Systems, Inc. | Raman-active taggants and their recognition |
| WO2001081340A2 (en) | 2000-04-24 | 2001-11-01 | Bristol-Myers Squibb Company | Heterocycles that are inhibitors of impdh enzyme |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| AU2001263083A1 (en) * | 2000-05-12 | 2001-11-26 | Ortho-Mcneil Pharmaceutical, Inc. | Biologically active 4h-benzo(1,4)oxazin-3-ones |
| AU2001271718A1 (en) | 2000-06-29 | 2002-01-14 | Smith Kline Beecham Corporation | Fatty acid synthase inhibitors |
| AU2001267878A1 (en) | 2000-07-05 | 2002-01-14 | Ajinomoto Co. Inc. | Hypoglycemics |
| US7354954B1 (en) * | 2000-08-10 | 2008-04-08 | Meythaler Jay M | Use of GABA agonists for treatment of spastic disorders, convulsions, and epilepsy |
| JP4790969B2 (ja) | 2000-08-11 | 2011-10-12 | 日本ケミファ株式会社 | ペルオキシソーム増殖剤応答性受容体δの活性化剤 |
| US6982348B2 (en) | 2001-01-26 | 2006-01-03 | Takeda Pharmaceutical Company Limited | Aminoethanol derivatives |
| CN1543451A (zh) | 2001-06-07 | 2004-11-03 | 过氧化物酶体增生剂激活的受体的调节剂 | |
| RU2341513C2 (ru) | 2001-06-12 | 2008-12-20 | Веллстат Терапьютикс Корпорейшн | Соединения для лечения метаболических заболеваний |
| DE10135027A1 (de) | 2001-07-18 | 2003-02-06 | Solvay Pharm Gmbh | Verwendung Trifluoracetylalkyl-substituierter Phenyl-, Phenol- und Benzoylderivate in der Behandlung und/oder Prophylaxe von Obestias und deren Begleit- und/oder Folgeerkrankungen |
| JP2003248008A (ja) * | 2001-12-18 | 2003-09-05 | Inst Of Physical & Chemical Res | 反応液の攪拌方法 |
| CA2502297C (en) | 2002-11-01 | 2011-12-13 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| ES2530235T3 (es) | 2003-02-13 | 2015-02-27 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos |
| ES2353601T3 (es) | 2003-04-15 | 2011-03-03 | Wellstat Therapeutics Corporation | Compuestos para el tratamiento de trastornos metabólicos. |
| CN1777576A (zh) | 2003-04-22 | 2006-05-24 | 维尔斯达医疗公司 | 用于治疗代谢紊乱的化合物 |
| CA2522738C (en) | 2003-04-30 | 2011-11-08 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| GB0314078D0 (en) | 2003-06-18 | 2003-07-23 | Astrazeneca Ab | Therapeutic agents |
| JP2007502815A (ja) | 2003-08-20 | 2007-02-15 | イーライ リリー アンド カンパニー | Ｐｐａｒ調節因子 |
| US20050262567A1 (en) * | 2004-05-19 | 2005-11-24 | Itshak Carmona | Systems and methods for computer security |
| US7319522B2 (en) * | 2004-05-27 | 2008-01-15 | Finesse Solutions Llc. | Systems and methods for in situ spectroscopic measurements |
| MX2007009124A (es) * | 2005-01-31 | 2007-10-08 | Univ Illinois | Metodos y dispositivos para caracterizar particulas en medios transparentes y turbios. |
| WO2006127133A2 (en) | 2005-04-01 | 2006-11-30 | Wellstat Therapeutics Corporation | Compounds for the treatment of metabolic disorders |
| WO2007117791A2 (en) | 2006-03-31 | 2007-10-18 | Wellstat Therapeutics Corporation | Combination treatment of metabolic disorders |
-
2002
- 2002-06-12 RU RU2004100306/04A patent/RU2341513C2/ru not_active IP Right Cessation
- 2002-06-12 CZ CZ20033394A patent/CZ20033394A3/cs unknown
- 2002-06-12 CN CNB028118812A patent/CN100344616C/zh not_active Expired - Fee Related
- 2002-06-12 UA UAA200709376A patent/UA104987C2/uk unknown
- 2002-06-12 US US10/167,839 patent/US7101910B2/en not_active Expired - Lifetime
- 2002-06-12 EP EP02744271.4A patent/EP1461323B1/en not_active Expired - Lifetime
- 2002-06-12 HU HU0600781A patent/HU230352B1/hu not_active IP Right Cessation
- 2002-06-12 ES ES02744271.4T patent/ES2441874T3/es not_active Expired - Lifetime
- 2002-06-12 KR KR1020107021892A patent/KR101059776B1/ko not_active Expired - Fee Related
- 2002-06-12 KR KR1020037016340A patent/KR100959356B1/ko not_active Expired - Fee Related
- 2002-06-12 CN CN2011100525843A patent/CN102151262A/zh active Pending
- 2002-06-12 CA CA2450221A patent/CA2450221C/en not_active Expired - Fee Related
- 2002-06-12 JP JP2003503168A patent/JP4711621B2/ja not_active Expired - Lifetime
- 2002-06-12 KR KR1020097009825A patent/KR100965201B1/ko not_active Expired - Fee Related
- 2002-06-12 US US10/481,042 patent/US7329782B2/en not_active Expired - Fee Related
- 2002-06-12 MX MXPA03011558A patent/MXPA03011558A/es active IP Right Grant
- 2002-06-12 CN CN2011100531191A patent/CN102140064A/zh active Pending
- 2002-06-12 KR KR1020107003045A patent/KR101009472B1/ko not_active Expired - Fee Related
- 2002-06-12 AU AU2002345625A patent/AU2002345625B2/en not_active Ceased
- 2002-06-12 WO PCT/US2002/018388 patent/WO2002100341A2/en not_active Ceased
- 2002-06-12 NZ NZ530051A patent/NZ530051A/en not_active IP Right Cessation
- 2002-06-12 IL IL15932002A patent/IL159320A0/xx unknown
- 2002-06-12 BR BRPI0210383-4A patent/BRPI0210383B1/pt not_active IP Right Cessation
- 2002-06-12 CN CN2007101492677A patent/CN101444496B/zh not_active Expired - Fee Related
- 2002-12-06 UA UA20031211545A patent/UA82831C2/uk unknown
-
2003
- 2003-10-14 US US10/684,660 patent/US6858602B2/en not_active Expired - Fee Related
- 2003-10-14 US US10/684,644 patent/US6924314B2/en not_active Expired - Fee Related
- 2003-10-14 US US10/684,730 patent/US6916848B2/en not_active Expired - Fee Related
- 2003-10-14 US US10/685,183 patent/US6946491B2/en not_active Expired - Lifetime
- 2003-10-14 US US10/684,735 patent/US7041659B2/en not_active Expired - Lifetime
- 2003-10-14 US US10/684,740 patent/US7045541B2/en not_active Expired - Fee Related
- 2003-12-11 IL IL159320A patent/IL159320A/en not_active IP Right Cessation
- 2003-12-11 ZA ZA2003/09627A patent/ZA200309627B/en unknown
- 2003-12-11 NO NO20035526A patent/NO333355B1/no not_active IP Right Cessation
-
2004
- 2004-06-10 US US10/865,088 patent/US20040242692A1/en not_active Abandoned
- 2004-07-16 US US10/892,950 patent/US7012071B2/en not_active Expired - Fee Related
- 2004-12-06 US US11/005,449 patent/US8487000B2/en not_active Expired - Fee Related
-
2006
- 2006-09-27 US US11/535,779 patent/US8552062B2/en not_active Expired - Fee Related
-
2007
- 2007-06-28 AU AU2007203009A patent/AU2007203009B2/en not_active Ceased
- 2007-07-02 US US11/772,511 patent/US20070249719A1/en not_active Abandoned
- 2007-07-02 US US11/772,560 patent/US8604083B2/en not_active Expired - Fee Related
- 2007-07-02 US US11/772,501 patent/US20070249696A1/en not_active Abandoned
- 2007-07-02 US US11/772,556 patent/US20070265323A1/en not_active Abandoned
- 2007-07-02 US US11/772,515 patent/US20070244171A1/en not_active Abandoned
- 2007-07-02 US US11/772,520 patent/US20070244141A1/en not_active Abandoned
- 2007-07-02 US US11/772,504 patent/US7851494B2/en not_active Expired - Fee Related
- 2007-08-20 US US11/841,508 patent/US20080015209A1/en not_active Abandoned
- 2007-08-24 US US11/844,432 patent/US7863475B2/en not_active Expired - Fee Related
- 2007-08-24 US US11/844,431 patent/US7547802B2/en not_active Expired - Fee Related
-
2008
- 2008-08-04 RU RU2008132204/04A patent/RU2502723C2/ru not_active IP Right Cessation
-
2009
- 2009-07-07 JP JP2009161269A patent/JP5477893B2/ja not_active Expired - Fee Related
- 2009-07-07 JP JP2009161270A patent/JP2009221232A/ja active Pending
-
2010
- 2010-12-08 IL IL209842A patent/IL209842A0/en unknown
-
2011
- 2011-03-08 AU AU2011201016A patent/AU2011201016B2/en not_active Ceased
-
2012
- 2012-04-24 IL IL219397A patent/IL219397A/en not_active IP Right Cessation
- 2012-04-24 IL IL219396A patent/IL219396A0/en unknown
-
2013
- 2013-02-08 NO NO20130218A patent/NO20130218L/no not_active Application Discontinuation
- 2013-03-06 JP JP2013043951A patent/JP2013129665A/ja not_active Withdrawn
- 2013-06-18 US US13/920,579 patent/US9133073B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2004100306A (ru) | Соединения для лечения метаболических заболеваний |